temp_copy

We’ve all been there. It’s exam week of your junior year of college with two papers due the day after a final. You’re a new faculty member with a semester of lectures to prepare and a lab to get started. You’re a tax accountant and it’s early April. There is simply too much to do and not enough hours in the day to get it all done while sleeping enough to keep your brain working like you need it to. In that situation, where do you stand on cognitive enhancement drugs? Most of us wouldn’t hesitate to grab a cup of coffee but what about a caffeine pill, or a friend’s Adderall? Many discussions about cognitive enhancement eventually come down to this question: where do we draw the line? Currently most of the cognitive enhancers that create unease for ethicists and the general public alike are prescription drugs that were originally meant to treat conditions recognized as out of the realm of “normal” such as diseases or deficits. Therefore, a key step in deciding where we should stand on th...

By Guest Contributor, Jagan Pillai, MD, PhD Dr. Jagan Pillai is a neurologist at the Lou Ruvo Center for Brain Health, Cleveland Clinic and works to help people with cognitive changes from neurological disorders and to develop diagnostic and treatment strategies in neurodegenerative diseases. He trained as a medical doctor at the University of Kerala, Trivandrum, India. He obtained a PhD from Northwestern University. He trained in Neurology at the Albert Einstein College of Medicine and at the University of California San Diego. As a neurologist interested in neurodegenerative disorders, I met Phil and a few others with preclinical Huntington’s disease (HD), on a trip to Phoenix, AZ to take in their perspectives. Phil is a self-appointed counselor, caretaker, and community leader of PHDs. He chuckles as he credits his accomplishments to having been born a PHD (in his lingo, Person with Huntington’s disease). HD is a neurodegenerative disorder caused by an expanded number of triplet re...

“What’s in a name? That which we call a rose, by any other name would smell as sweet.” This is the famous question posed by Juliet in the immortalized balcony scene.  And while Shakespeare could afford to question the idea, patients with mental disorders, scientists who study the disorders, and the insurance agents that fund the aid have not yet found a way to do without names. In a recent interview, Steven Hyman puts this sentiment in his own words: “Classifications are, in the end, cognitive schemata that we impose on data in order to organize and manipulate it. Many disorders are better represented for scientific purposes, but also for setting rational thresholds for treatments as continuous quantitative dimensions.” Image of Dr. Hyman: http://news.harvard.edu/gazette/story/2010/12/hyman_release/ Coinciding with the 2nd Annual Neuroethics Award , several staff members of Emory’s Center for Ethics interviewed Dr. Steven Hyman , the esteemed Director of the Broad Institute S...